Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793

Eli Lilly (LLY) has an average outperform rating and a price target range of $540 to $1,100, according to analysts polled by Capital IQ.Price: 955.75, Change: +5.29, Percent Change: +0.56

MT NewswiresJul 16 08:18 ET

Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025

Barclays analyst Carter Gould maintains $Eli Lilly and Co(LLY.US)$ with a buy rating, and maintains the target price at $1,025.According to TipRanks data, the analyst has a success rate of 59.5% and

Moomoo NewsJul 16 05:33 ET · Ratings

Eli Lilly and Co Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 -7.76% Cantor Fitzgerald $885 → $885 Reiterates Overweight → Overweight 07/11/2024 4.22%

BenzingaJul 15 09:05 ET

Nomura maintains a 'buy' rating on Innovent Bio and raises the target price to HKD 55.87.

Nomura releases research report, maintaining a "buy" rating for Innovent Bio (01801), anticipating the company's sales will continue to grow healthily in the first half of the year, and the target price has been raised from HKD 55.31 to HKD 55.87. The bank stated that it adjusted Innovent Bio's sales forecasts for the next two years by 1% and 5%, respectively, to reflect the decline in sales of the BCMA multiple myeloma CAR-T therapy Fucaso, a cooperative project with Deerfield Capital, as well as the expectation of reduced sales of diabetes drug Mazdutide, co-developed with Eli Lilly and Co., due to increased market competition. Next year's sales forecast has been reduced from RMB 2.1 billion to 18 billion yuan.

新浪港股Jul 16 00:09 ET

Q2 Earnings Season Scorecard and Analyst Reports for Microsoft, Eli Lilly & UnitedHealth

The Zacks Research Daily presents the best research output of our analyst team.

Yahoo FinanceJul 15 15:05 ET

This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co (NYSE:LLY) and maintained a price target of $885.The company is slated to report its second-

BenzingaJul 15 13:13 ET